Are Target Urate and Remission Possible in Severe Gout? A Five-year Cohort Study
Authors:
- Claudia Alvarado-De la BarreraCBClaudia Alvarado-De la Barrera
- Carlos Omar López-LópezCLCarlos Omar López-López
- Everardo Álvarez-HernándezEÁEverardo Álvarez-Hernández
- Ingris Peláez-BallestasIPIngris Peláez-Ballestas
- Citlallyc Gómez-RuizCGCitlallyc Gómez-Ruiz
- Rubén Burgos-VargasRBRubén Burgos-Vargas
- Janitzia Vázquez-MelladoJVJanitzia Vázquez-Mellado
- 1 May 2019
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 47 (1) , 132-139
Abstract
Objective.: Determine the proportion of patients achieving target serum urate (SU), defined as < 6 mg/dl for patients with non-severe gout and < 5 mg/dl for patients with severe gout, as well as the proportion of patients achieving remission after 5 years of followup.Methods.: Patients from the Gout Study Group (GRESGO) cohort were evaluated at 6-month intervals. Demographic and clinical data were obtained at baseline. Visits included assessments of serum urate, flares, tophus burden, health-related quality of life using the EQ-5D, activity limitations using the Health Assessment Questionnaire adapted for gout, and pain level and patient’s global assessment using visual analog scales. Treatment for gout and associated diseases was prescribed according to guidelines and available drugs.Results.: Of 500 patients studied, 221 had severe gout (44%) and 279 had non-severe gout (56%) at baseline. No significant differences were observed across the study in percentages of severe gout versus non-severe gout patients achieving SU 6 mg/dl or 5 mg/dl. The highest proportion of patients achieving target SU (50–70%) and remission (39%) were found after 3–4 years of followup. In the fifth year, these proportions decreased and 28% of the patients were in remission, but only 40 patients remained in the study. None of the patients with severe gout achieved remission.Conclusion.: In patients with severe gout, target SU was hard to achieve and remission was not possible. The main obstacles for target SU and gout remission include poor medication adherence, persistent tophi, and loss to followup.Keywords
This publication has 28 references indexed in Scilit:
- Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational studyAnnals of the Rheumatic Diseases, 2013
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Understanding Reasons for and Outcomes of Patients Lost to Follow-Up in Antiretroviral Therapy Programs in Africa Through a Sampling-Based ApproachJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Does prolonged systemic glucocorticoid use increase risk of tophus formation among gouty arthritis patients?International Journal of Rheumatic Diseases, 2009
- A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic goutAnnals of the Rheumatic Diseases, 2008
- The Use of Glucocorticoids by Rheumatologic Patients Before Attending a Specialized Department in MéxicoJCR: Journal of Clinical Rheumatology, 2008
- Validation of the Health Assessment Questionnaire disability index in patients with goutArthritis Care & Research, 2008
- EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)Annals of the Rheumatic Diseases, 2006
- Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?Hypertension, 2003
- Drug prescription and self-medication in India: An exploratory surveySocial Science & Medicine, 1987